New Hope for Bipolar Patients


Take Part in an FDA Approved Study for Bipolar Disorder with the latest Deep TMS Technology
About Brainsway Deep TMS

Brainsway* Deep TMS is an innovative, revolutionary technology for the treatment of brain disorders such as Bipolar Disorder. Deep TMS non-invasively stimulates the brain regions responsible for Bipolar Disorder using brief magnetic fields, at an amplitude similar to that used in magnetic resonance imaging (MRI) systems. The device has been cleared by the FDA for treating depression, and has been studied in over 60 clinical trials around the world.

The treatment does not entail systemic side effects, which are effects deriving from medication entering the bloodstream and circulating throughout the body.

Brainsway Deep TMS treatment requires only brief daily sessions over a few weeks, without indefinite or permanent medication intake.

About the Study

The aim of the study is to evaluate the efficacy and safety of deep brain rTMS in subjects with Bipolar Disorder, taking mood stabilizers and previously unsuccessfully treated with antidepressant medications. The treatment will take place in leading medical centers around the world and is administered by experts. It entails no surgery, hospitalization or medications, and is based on 24 brief sessions of less than 20 minutes over a period of 6 weeks and additional 2 weeks of follow-up visits for testing improvement. During the treatment, the patient is comfortably seated in a chair, and a cushioned helmet placed over the head generates brief magnetic fields.

Immediately after each session, patients can drive home independently and resume their daily routine. The study has been approved by the FDA.

Patient Criteria

Study participants should meet the following criteria: Aged 22-68 and diagnosed with Bipolar Disorder and may be of all racial, ethnic and gender categories, with partial or no response to treatment and have not had any prior TMS treatment.

If you have been diagnosed with Bipolar Disorder, you may be eligible for the study.

Study Locations

Advanced Mental Health Care Inc. – Juno Beach, Florida, USA
Contact information: Elyssa Sisko, 561-2678876,

Advanced Mental Health Care Inc. – Royal Palm Beach, Florida, USA
Contact information: Elyssa Sisko, 561-2678876,

Brainefit LLC (Davis, California) – Illinois, USA
Contact information:

Center for Addiction & Mental Health (CAMH) – Toronto, Canada
Contact information: Melissa Daigle, 416-535-8501 ext. 36434,

Johns Hopkins University– Baltimore,MD,USA
Contact information: Michael Tibbs, 410-614-1732,

Medical University Of South Carolina (MUSC)– Charleston, SC,USA
Contact information: Jkeonye Moss, 843-876-5141,

Premier Psychiatric Group- Omaha, Nebraska, USA
Contact information: Kelly Espenschade,

Senior Adults Specialty Research- Austin, Texas, USA
Contact information: Meredith Draper, 512-407-8628,

University of Texas Southwestern Medical Center (Texas) – Dallas, Texas, USA
Contact information: Aatika Parwaiz, 214-648-2807,